Research Analysts Offer Predictions for QNCX FY2024 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX) – Analysts at Brookline Capital Management issued their FY2024 EPS estimates for shares of Quince Therapeutics in a research note issued to investors on Wednesday, December 18th. Brookline Capital Management analyst K. Raja expects that the company will earn ($1.21) per share for the year. Brookline Capital Management has a “Buy” rating and a $9.00 price target on the stock. Brookline Capital Management also issued estimates for Quince Therapeutics’ Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.52 EPS.

Several other equities research analysts also recently commented on QNCX. Rodman & Renshaw started coverage on shares of Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 target price on the stock. Maxim Group started coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They set a “buy” rating and a $6.00 price target on the stock. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 29th. Finally, EF Hutton Acquisition Co. I raised Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.67.

Quince Therapeutics Price Performance

Quince Therapeutics stock opened at $1.78 on Friday. The stock has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $1.03. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The company has a market capitalization of $78.32 million, a PE ratio of -1.44 and a beta of 0.74. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33.

Institutional Investors Weigh In On Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC increased its position in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.